For additional information about the HPD Program, including details on data sources, populations included, and data elements available, see HPD Public Reporting FAQ, HPD Resources, and the HPD Snapshot (and its Technical Note)
Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5
These are both versions designed to treat Type II diabetes
Most patients notice changes within 2-3 months of starting treatment, often coinciding with the first 5-10% weight loss
Enjoy this phase while it lasts, because the rate naturally slows as you approach your bodys new equilibrium
Headaches Headaches are reported by approximately 10% to 15% of GLP-1 users, typically in the first few weeks